Should patients receive a test dose of bleomycin? If yes, should the test dose be administered with every dose or just the initial dose?
The Advisor Forum panel answers nurses’ questions about hair loss, mammography timing, and turnaround time for oral chemotherapy agents.
A poly(ADP-ribose) polymerase (PARP) inhibitor that has shown promising anticancer activity in the presence of BRCA1 or BRCA2 gene mutations also appears to be effective in the treatment of more common, nonhereditary ovarian tumors.
The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
CIPN is a debilitating adverse effect that can lead to reduced doses that hinder treatment effectiveness or early discontinuation of therapy.
This patient fact sheet answers some commonly asked questions about prostate cancer and bone health. It also discusses steps you can take to care for your bones.